Normocarb Hf 25 is a drug owned by Dialysis Supplies Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 04, 2023. Details of Normocarb Hf 25's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7300674 | Sterile low bicarbonate dialysis concentrate solutions |
Mar, 2023
(2 years ago) |
Expired
|
| US5945449 | Sterile bicarbonate concentrate |
Oct, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Normocarb Hf 25's patents.
Latest Legal Activities on Normocarb Hf 25's Patents
Given below is the list of recent legal activities going on the following patents of Normocarb Hf 25.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 30 Dec, 2019 | US7300674 |
| Maintenance Fee Reminder Mailed Critical | 15 Jul, 2019 | US7300674 |
| Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 15 Sep, 2017 | US7300674 |
| Surcharge, Petition to Accept Pymt After Exp, Unintentional Critical | 15 Sep, 2017 | US7300674 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2017 | US7300674 |
| Petition to Accept Late Payment of Maintenance Fee Payment Filed Critical | 15 Sep, 2017 | US7300674 |
| Mail-Petition Decision - Accept Late Payment of Maintenance Fees - Granted Critical | 15 Sep, 2017 | US7300674 |
| Expire Patent Critical | 24 Dec, 2015 | US7300674 |
| Patent Issue Date Used in PTA Calculation Critical | 27 Nov, 2007 | US7300674 |
| Recordation of Patent Grant Mailed Critical | 27 Nov, 2007 | US7300674 |
FDA has granted several exclusivities to Normocarb Hf 25. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Normocarb Hf 25, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Normocarb Hf 25.
Exclusivity Information
Normocarb Hf 25 holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Normocarb Hf 25's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 26, 2013 |
US patents provide insights into the exclusivity only within the United States, but Normocarb Hf 25 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Normocarb Hf 25's family patents as well as insights into ongoing legal events on those patents.
Normocarb Hf 25's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Normocarb Hf 25's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 04, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Normocarb Hf 25 Generics:
There are no approved generic versions for Normocarb Hf 25 as of now.
Alternative Brands for Normocarb Hf 25
Normocarb Hf 25 which is used for continuous renal replacement therapy., has several other brand drugs in the same treatment category and using the same active ingredient (Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Dialysis Sups |
| |||
About Normocarb Hf 25
Normocarb Hf 25 is a drug owned by Dialysis Supplies Inc. It is used for continuous renal replacement therapy. Normocarb Hf 25 uses Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride as an active ingredient. Normocarb Hf 25 was launched by Dialysis Sups in 2006.
Approval Date:
Normocarb Hf 25 was approved by FDA for market use on 26 July, 2006.
Active Ingredient:
Normocarb Hf 25 uses Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride as the active ingredient. Check out other Drugs and Companies using Magnesium Chloride; Sodium Bicarbonate; Sodium Chloride ingredient
Treatment:
Normocarb Hf 25 is used for continuous renal replacement therapy.
Dosage:
Normocarb Hf 25 is available in solution form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.21GM/100ML;2.8GM/100ML;9.07GM/100ML | SOLUTION | Prescription | INJECTION |